Model-free group analysis shows altered BOLD FMRI networks in dementia. by Rombouts, SA, Damoiseaux, J, Goekoop, R, Barkhof, F, Scheltens, P, Smith, S, Beckmann, C

Consistent resting-state networks across healthy subjects. by Damoiseaux, J, Rombouts, SA, Barkhof, F, Scheltens, P, Stam, C, Smith, S, Beckmann, C

Psychosis in behavioral variant frontotemporal dementia by Gossink FT, Vijverberg EGB, Krudop W, Scheltens P, Stek ML, Pijnenburg YAL, Dols A

Get full text

Reduced resting-state brain activity in the "default network" in normal aging. by Damoiseaux, J, Beckmann, C, Arigita, E, Barkhof, F, Scheltens, P, Stam, C, Smith, S, Rombouts, SA

Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. by Zarei, M, Damoiseaux, J, Morgese, C, Beckmann, C, Smith, S, Matthews, P, Scheltens, P, Rombouts, SA, Barkhof, F

White matter tract integrity in aging and Alzheimer's disease. by Damoiseaux, J, Smith, S, Witter, M, Sanz-Arigita, E, Barkhof, F, Scheltens, P, Stam, C, Zarei, M, Rombouts, SA

Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis by Harper, L, Bouwman, F, Burton, E, Barkhof, F, Scheltens, P, O'Brien, J, Fox, N, Ridgway, G, Schott, J

MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases by Harper, L, Fumagalli, G, Barkhof, F, Scheltens, P, O'Brien, J, Bouwman, F, Burton, E, Rohrer, J, Fox, N, Ridgway, G, Schott, J

Protocols to demonstrate slowing of Alzheimer disease progression - Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines by Bodick, N, Forette, F, Hadler, D, Harvey, R, Leber, P, McKeith, I, Riekkinen, P, Rossor, M, Scheltens, P, Shimohama, S, Spiegel, R, Tanaka, S, Thal, L, Urata, Y, Whitehouse, P, Wilcock, G

Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Pro... by Bodick, N, Forette, F, Hadler, D, Harvey, R, Leber, P, McKeith, I, Riekkinen, P, Rossor, M, Scheltens, P, Shimohama, S, Spiegel, R, Tanaka, S, Thal, L, Urata, Y, Whitehouse, P, Wilcock, G

Biomarkers for Alzheimer's disease therapeutic trials by Hampel, H, Wilcock, G, Andrieu, S, Aisen, P, Blennow, K, Broich, K, Carrillo, M, Fox, N, Frisoni, G, Isaac, M, Lovestone, S, Nordberg, A, Prvulovic, D, Sampaio, C, Scheltens, P, Weiner, M, Winblad, B, Coley, N, Vellas, B

Biomarkers for Alzheimer's disease therapeutic trials. by Hampel, H, Wilcock, G, Andrieu, S, Aisen, P, Blennow, K, Broich, K, Carrillo, M, Fox, N, Frisoni, G, Isaac, M, Lovestone, S, Nordberg, A, Prvulovic, D, Sampaio, C, Scheltens, P, Weiner, M, Winblad, B, Coley, N, Vellas, B

Circulating metabolites are associated with brain atrophy and white matter hyperintensities by de Leeuw, FA, Karamujić-Čomić, H, Tijms, BM, Peeters, CFW, Kester, MI, Scheltens, P, Ahmad, S, Vojinovic, D, Adams, HHH, Hankemeier, T, Bos, D, van der Lugt, A, Vernooij, MW, Ikram, MA, Amin, N, Barkhof, F, Teunissen, CE, van Duijn, CM, van der Flier, WM

CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers by Ahmad, S, del Campo Milan, M, Hansson, O, Demirkan, A, Agustin, R, Sáez, ME, Giagtzoglou, N, Cabrera-Socorro, A, Bakker, MHM, Ramirez, A, Hankemeier, T, Stomrud, E, Mattsson-Carlgren, N, Scheltens, P, van der Flier, WM, Ikram, MA, Malarstig, A, Teunissen, CE, Amin, N, van Duijn, CM

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. by Vellas, B, Carrillo, M, Sampaio, C, Brashear, H, Siemers, E, Hampel, H, Schneider, L, Weiner, M, Doody, R, Khachaturian, Z, Cedarbaum, J, Grundman, M, Broich, K, Giacobini, E, Dubois, B, Sperling, R, Wilcock, G, Fox, N, Scheltens, P, Touchon, J, Hendrix, S, Andrieu, S, Aisen, P

Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the Development of Screening guidelines and diagnostic Criteria for Predementi... by Sikkes, SA, Visser, P, Knol, D, de Lange-de Klerk, E, Tsolaki, M, Frisoni, G, Nobili, F, Spiru, L, Rigaud, A, Frölich, L, Rikkert, M, Soininen, H, Touchon, J, Wilcock, G, Boada, M, Hampel, H, Bullock, R, Vellas, B, Pijnenburg, Y, Scheltens, P, Verhey, F, Uitdehaag, B

Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. by Norberg, J, Graff, C, Almkvist, O, Ewers, M, Frisoni, G, Frölich, L, Hampel, H, Jones, R, Kehoe, P, Lenoir, H, Minthon, L, Nobili, F, Olde Rikkert, M, Rigaud, A, Scheltens, P, Soininen, H, Spiru, L, Tsolaki, M, Wahlund, L, Vellas, B, Wilcock, G, Elias-Sonnenschein, L, Verhey, F, Visser, P

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result by Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S

Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study. by Visser, P, Verhey, F, Boada, M, Bullock, R, De Deyn, P, Frisoni, G, Frolich, L, Hampel, H, Jolles, J, Jones, R, Minthon, L, Nobili, F, Olde Rikkert, M, Ousset, P, Rigaud, A, Scheltens, P, Soininen, H, Spiru, L, Touchon, J, Tsolaki, M, Vellas, B, Wahlund, L, Wilcock, G, Winblad, B

The association between APOE ε4 and Alzheimer-type dementia among memory clinic patients is confined to those with a higher education. The DESCRIPA Study. by Vermeiren, A, Bosma, H, Visser, P, Zeegers, M, Graff, C, Ewers, M, Frisoni, G, Frölich, L, Hampel, H, Jones, R, Kehoe, P, Lenoir, H, Minthon, L, Nobili, F, Olde Rikkert, M, Rigaud, A, Scheltens, P, Soininen, H, Spiru, L, Tsolaki, M, Wahlund, L, Vellas, B, Wilcock, G, Elias-Sonnenschein, L, Verhey, F